Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 16, 2023 at 04:15 pm EDT
Share
Sana Biotechnology, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 80.44 million compared to USD 110.73 million a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 0.6 a year ago. Diluted loss per share from continuing operations was USD 0.42 compared to USD 0.6 a year ago.
For the full year, the company reported net loss was USD 269.48 million compared to USD 355.93 million a year ago. Basic loss per share from continuing operations was USD 1.43 compared to USD 2.14 a year ago. Diluted loss per share from continuing operations was USD 1.43 compared to USD 2.14 a year ago.
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
SANA BIOTECHNOLOGY, INC. 
